TerminatedPhase 2NCT02599129

A Study of Secukinumab for the Treatment of Alopecia Areata

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Icahn School of Medicine at Mount Sinai
Principal Investigator
Mark Lebwohl, MD
Icahn School of Medicine at Mount Sinai
Intervention
Secukinumab(drug)
Enrollment
11 enrolled
Eligibility
18 years · All sexes
Timeline
20152016

Study locations (1)

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02599129 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials